Novo Nordisk EBITDA 2012-2026 | NVO

Novo Nordisk EBITDA for the quarter ending March 31, 2026 was $9.890B, a 64.45% increase year-over-year.

  • Novo Nordisk 2025 EBITDA was 22.656B, a 5.97% increase from 2024.
  • Novo Nordisk 2024 EBITDA was 21.38B, a 31.48% increase from 2023.
  • Novo Nordisk 2023 EBITDA was 16.261B, a 39.75% increase from 2022.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Novo Nordisk EBITDA 2012-2026 | NVO

  • Novo Nordisk 2025 EBITDA was 22.656B, a 5.97% increase from 2024.
  • Novo Nordisk 2024 EBITDA was 21.38B, a 31.48% increase from 2023.
  • Novo Nordisk 2023 EBITDA was 16.261B, a 39.75% increase from 2022.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$887.6B
Johnson & Johnson (JNJ)$574.4B
AbbVie (ABBV)$367.7B
Roche Holding AG (RHHBY)$318.8B
Merck (MRK)$299.9B
Novartis AG (NVS)$294B
Pfizer (PFE)$153.1B
Sanofi (SNY)$114B
Bayer (BAYRY)$46.2B
Innoviva (INVA)$1.8B